Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mu Sun

Showing results (81-90 of 349) with videos related to

Pageof 35
Sort By:
Cancer Research and Treatment|July 26, 2024
Salvage Radiotherapy for Loco-regional Recurrence of Esophageal Cancer Following SurgeryWon Kyung Cho, Jae Myoung Noh, Dongryul Oh, et al.
Scientific Reports|October 3, 2019
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumabYeonghee Eun, In Young Kim, Jong-Mu Sun, et al.
Molecular and Cellular Neurosciences|May 4, 2004
Reduced GABAergic transmission and number of hippocampal perisomatic inhibitory synapses in juvenile mice deficient in the neural cell adhesion molecule L1Armen K Saghatelyan, Alexander G Nikonenko, Mu Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2017
KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung AdenocarcinomaJang Ho Cho, Bo Mi Ku, Jong-Mu Sun, et al.
BMC Infectious Diseases|May 11, 2017
A case control study on family history as a risk factor for herpes zoster and associated outcomes, Beijing, ChinaLuodan Suo, Li Lu, Juan Li, et al.
Plos One|April 12, 2018
Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical modelBo Mi Ku, Moon Ki Choi, Jong-Mu Sun, et al.
Investigational New Drugs|October 25, 2014
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancerBo Mi Ku, Eun Hye Jho, Yeon-Hee Bae, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2014
A new KIT gene mutation in thymic cancer and a promising response to imatinibSung Hee Lim, Ji-Yun Lee, Jong-Mu Sun, et al.
BMC Cancer|August 8, 2020
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in KoreaHyera Kim, Minsuk Kwon, Binnari Kim, et al.
Translational Lung Cancer Research|November 19, 2020
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancerHyun Ae Jung, Sook Young Woo, Se-Hoon Lee, et al.
Pageof 35

Showing results (81-90 of 349) with videos related to

Sort By:
Pageof 35
Cancer Research and Treatment|July 26, 2024
Salvage Radiotherapy for Loco-regional Recurrence of Esophageal Cancer Following SurgeryWon Kyung Cho, Jae Myoung Noh, Dongryul Oh, et al.
Scientific Reports|October 3, 2019
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumabYeonghee Eun, In Young Kim, Jong-Mu Sun, et al.
Molecular and Cellular Neurosciences|May 4, 2004
Reduced GABAergic transmission and number of hippocampal perisomatic inhibitory synapses in juvenile mice deficient in the neural cell adhesion molecule L1Armen K Saghatelyan, Alexander G Nikonenko, Mu Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2017
KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung AdenocarcinomaJang Ho Cho, Bo Mi Ku, Jong-Mu Sun, et al.
BMC Infectious Diseases|May 11, 2017
A case control study on family history as a risk factor for herpes zoster and associated outcomes, Beijing, ChinaLuodan Suo, Li Lu, Juan Li, et al.
Plos One|April 12, 2018
Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical modelBo Mi Ku, Moon Ki Choi, Jong-Mu Sun, et al.
Investigational New Drugs|October 25, 2014
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancerBo Mi Ku, Eun Hye Jho, Yeon-Hee Bae, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2014
A new KIT gene mutation in thymic cancer and a promising response to imatinibSung Hee Lim, Ji-Yun Lee, Jong-Mu Sun, et al.
BMC Cancer|August 8, 2020
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in KoreaHyera Kim, Minsuk Kwon, Binnari Kim, et al.
Translational Lung Cancer Research|November 19, 2020
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancerHyun Ae Jung, Sook Young Woo, Se-Hoon Lee, et al.
Pageof 35